COVID-19: FDA grants “Actemra” urgently: reduces mortality
-Rheumatoid arthritis drug appears as a new corona treatment drug-
FDA = Food and Drug Administration:
Infected with the new coronavirus,
As a therapeutic drug for inpatients
We have approved the emergency use of rheumatoid arthritis drugs developed by Chugai Pharmaceutical Co., Ltd.
Emergency use of rheumatoid arthritis drugs:
The FDA has approved emergency use of “Actemra,” a treatment for rheumatoid arthritis.
Chugai:
It was jointly developed by a group of specially appointed professors Tadamitsu Kishimoto of Osaka University.
For inpatients:
Infected with the new coronavirus,
Needs treatment such as respirator,
For inpatients receiving steroidal anti-inflammatory drugs.
Effect of lowering mortality:
In 4 clinical trials
Reduce the mortality rate of inpatients,
It had the effect of shortening the length of hospital stay.
Actemra has the function of suppressing inflammation.
It is approved worldwide as a treatment for rheumatoid arthritis.
TBS NEWS
https://news.tbs.co.jp/newseye/tbs_newseye4300835.html
Roche’s Actemra gets U.S. FDA approval for hospitalized COVID-19 patients
(Reuters)
The U.S. Food and Drug Administration
issued an emergency use authorization (EUA) for the drug Actemra for the treatment of hospitalized COVID-19 adults and pediatric patients,
the health agency said on Thursday.
The EUA was issued to Genentech, a subsidiary of Roche Holding AG.
The drug can be used to treat patients who are receiving systemic corticosteroids
and
require supplemental oxygen,
non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation,FDA said.
In the clinical trials,
Actemra was shown to reduce the risk of death and time taken to recover by hospitalised patients,the FDA added.
Article [AMP] | Reuters
https://jp.reuters.com/article/health-coronavirus-fda-actemra-idCNL3N2O64HV